Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PRKCA | P17252 | 1/20 | 0.33 |
| ▸ | BTN3A1 | O00481 | 4/20 | 0.32 |
| ▸ | ENO1 | P06733 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1507155 | 0.85 | PRKCA (0.35) | ALDH1A1PRKCABTN3A1ENO1 | |
| SCHEMBL18655541 | 0.84 | PRKCA (0.33) | ALDH1A1PRKCABTN3A1ENO1 | |
| Hydrochloric Acid SCHEMBL18757103 | 0.82 | PRKCA (0.32) | ALDH1A1PRKCABTN3A1ENO1 | |
| SCHEMBL6885640 | 0.82 | CYP1A2 (0.36) | TDP1ALDH1A1 | |
| SCHEMBL6882142 | 0.80 | ACHE (0.40) | ACHEALDH1A1 | |
| SCHEMBL18655573 | 0.79 | TDP1 (0.41) | TDP1ACHEALDH1A1 | |
| SCHEMBL18631716 | 0.78 | IDO1 (0.36) | ACHE | |
| SCHEMBL681950 | 0.77 | PRKCA (0.46) | ALDH1A1PRKCABTN3A1ENO1 | |
| SCHEMBL2949105 | 0.76 | PRKCA (0.37) | ALDH1A1PRKCABTN3A1ENO1 | |
| SCHEMBL6882634 | 0.76 | LMNA (0.36) | ACHEPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9630917-B2 | Cysteamine prodrugs, pharmaceutical compositions thereof, and methods of use | Nguyen, Mark Quang (US) | 2017-04-25 | — | — | US | disclosed |
| US-9630917-B2 | Cysteamine prodrugs, pharmaceutical compositions thereof, and methods of use | Nguyen, Mark Quang (US) | 2017-04-25 | — | — | US | disclosed |
| US-20170081279-A1 | CYSTEAMINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-03-23 | — | — | US | disclosed |
| US-20170081279-A1 | CYSTEAMINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081279-A1 | CYSTEAMINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | GLS, GLS2, CTH | TDP1 1574/4885ACHE 1920/4885ALDH1A1 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.